Mayo Clinic News Network

News Resources


Share this:

Posted by Dana Sparks (@danasparks) · Aug 12, 2013

Preclinical Tests May Lead to New Treatment Approach for CNS Lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open on all three Mayo Clinic campuses — FloridaMinnesota and Arizona — follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma.

Mayo Clinic oncologist Han Tun, M.D., says, “We believe pomalidomide could be beneficial in patients with this cancer because it does two things that most anti-cancer drugs do not do. The drug has excellent brain penetration, which is a requirement in treatment of brain tumors. The other interesting thing is that it is not only active directly against lymphoma cells but also alters the tumor microenvironment.”

Details of the preclinical testing are available in the science journal PLOS ONE.

Click here for news release

brain tumors central nervous system CNS Florida Lymphoma multiple myeloma oncology cancer Dr. Han Tun

 

Have something to say? Please login or register to respond.